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previous studies have demonstrated that thyroid nodules 
are found in 4-8% of the general population with the use 
of palpation, in 19-67% of patients with the use of US 
and in 50% of autopsy specimens (1-4). Malignancies have 
been found in 9-15% of the nodules that were evaluated 
with fi ne-needle aspiration (FNA) biopsy (1-5). The same as 
in other countries, the incidence of thyroid cancer is rapidly 
increasing in Korea and it is becoming the most common 
cancer in Korean women, followed by breast cancer, 
according to the recent report (6). 
Thyroid nodules are especially more common in 
elderly patients, female patients, patients with iodine 
defi ciency and patients with a history of neck irradiation. 
Uncommonly, a thyroid nodule can cause local compression 
or hyperthyroidism and so it should be treated accordingly. 
INTRODUCTION
Thyroid nodules are a common clinical problem and the 
incidence of thyroid nodules has increased with the recently 
increased use of thyroid ultrasonography (US). Several 
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Yet the clinical importance of thyroid nodules lies in 
the detection of malignancy, and malignancy comprises 
approximately 5% of all thyroid nodules irrespective of 
the size (7). The risk factors associated with an increased 
likelihood of a malignancy in thyroid nodules include a 
previous history of irradiation, a family history of medullary 
thyroid carcinoma or multiple endocrine neoplasia (MEN) 
type II, patients who are younger than 20 years or older 
than 60 years, male patients, rapid growth of a nodule, a 
nodule with a fi rm and hard consistency, an inconspicuous 
margin of the nodule on palpation, the presence of enlarged 
cervical lymph nodes and the presence of a fi xed nodule (4, 
7, 8). 
Among the modern imaging modalities, high-resolution US 
is the most sensitive diagnostic modality for the detection 
of the thyroid nodules and it is necessary to perform US 
for the nodules found after palpation (8). In addition, US 
can evaluate the size and characteristic of nonpalpable 
nodules, it can guide FNA for thyroid nodules and it can 
diagnose lymph node metastasis. Although thyroid US has 
been regarded as the mainstay for the management of the 
thyroid nodules, there has been no clear consensus on 
the US-based management such as follow-up for thyroid 
US and the selection of a nodule for FNA biopsies, as well 
as the standardized terminology for thyroid US. There are 
many different guidelines and recommendations for the 
management of thyroid nodules detected on US, and these 
recommendations and guidelines have been described by 
different organizations (4, 7, 8). 
The thyroid study group of the Korean Society of Radiology 
(TSGKSR) organized a task force group in 2005 and the task 
force members undertook a complete literature review in 
2006 and 2009. The relevant articles from 1985 to 2009 
were collected by searching MEDLINE using the following 
search terms: thyroid nodule, thyroid malignancy, thyroid 
carcinoma, US, aspiration biopsy, biopsy and follow-up. 
Since the TSGKSR fi rst organized the taskforce team to 
provide recommendations for thyroid US and to undertake a 
multicenter study (9), the thyroid study group published its 
recommendations for the US management of thyroid nodules 
in 2006 (10) and the group revised the recommendations 
in 2009. Meanwhile, the TSGKSR has been transformed into 
the Korean Society of Thyroid Radiology (KSThR). By the 
inclusion of new references (up to May 2010), we provide 
here this article for any radiologists who perform thyroid 
US. We have reviewed the standardized terminology for 
thyroid US as proposed by our task force, the US fi ndings of 
thyroid nodules and the strategy for US follow-up and US-
FNA biopsies. We also discuss the current issues for the role 
of US screening for thyroid nodules.
ANALYSIS OF THE US FINDINGS OF THYROID 
NODULES
 
THE NODULE SIZE
The size of a thyroid nodule is not helpful for 
distinguishing a malignant nodule from a benign nodule. 
The nodule size should be precisely documented for the 
purpose of follow-up. Although malignancy is believed 
to grow more prominently than benignancy, even benign 
nodules can grow with time and about 90% of benign 
nodules have demonstrated an increase in volume by 15% 
over a 5-year follow-up period (11, 12). Cystic nodule 
showed slower growth than did solid nodule (13). The rapid 
growth of thyroid nodules can be seen for anaplastic thyroid 
carcinoma, lymphoma, sarcoma and rarely for high-grade 
carcinoma (14).
Although in principle the size of thyroid nodules should 
be measured in all three dimensions, only the maximal 
diameter of the nodule can be measured and documented. 
When measuring the nodule size, it is advisable to locate 
the calipers at the outer margin of the halo of the nodule 
(4). 
There has been no clear consensus on the defi nition 
of nodule growth. According to the American Thyroid 
Association (ATA) guideline, a reasonable defi nition of 
growth is a 20% increase in the nodule diameter with a 
minimum increase in two or more dimensions of at least 
2 mm, which is roughly a 50% increase in volume (8). 
Some groups prefer a 15% increase in the nodule volume 
as a defi nition of nodule growth (13, 15). Yet substantial 
interobserver bias has previously been observed, and 
especially for less than a 50% volume increase in small 
nodules (16). 
Accordingly, we recommend the defi nition of nodule 
growth as a 20% increase in the nodule diameter or a 50% 
increase in the nodule volume. 
INTERNAL CONTENT 
Although a mainly cystic nodule is rare in thyroid 
carcinoma, a cystic component is found in 13-26% of 
all thyroid carcinomas (17, 18). Approximately 5% of all 
partially cystic nodules have been reported to be malignant 
in a recent study (19). In this case, the presence of a solid 
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component with vascularity, an eccentric location of the 
solid portion or microcalcifi cation may suggest malignant 
nodule and especially papillary thyroid carcinoma (17, 19, 
20). A nodule with multiple microcystic spaces separated 
by thin septae or intervening isoechoic parenchyma (a 
‘spongiform’ appearance) is regarded as a benign nodule 
with a specifi city of 99.7-100% (9, 21, 22).
We suggest the following terminology for the internal 
content of a nodule. The internal content of a nodule is 
categorized in terms of the ratio of the cystic portion to 
the solid portion in the nodule: solid (≤ 10% of the cystic 
portion), predominantly solid (> 10% of the cystic portion 
and ≤ 50% of the cystic portion), predominantly cystic 
(> 50% of the cystic portion and ≤ 90% of the cystic 
portion) and cystic (> 90% of the cystic portion) (9) 
(Fig. 1). The defi nition of a spongiform appearance is the 
aggregation of multiple microcystic components in more 
than 50% of the volume of the nodule (9) (Fig. 2). 
NODULE SHAPE
The shape of a nodule has gained diagnostic importance 
for the differentiation of benign and malignant nodules 
since this was fi rst described in a study by Kim et al. (23). 
Kim and colleagues reported that a taller-than-wide shape 
showed a specifi city of 93% for the diagnosis of malignant 
nodules. In a larger multicenter study, a taller-than-wide 
shape was shown to be highly suggestive of a malignancy, 
with a specifi city of 89% and a positive predictive value of 
86% (9).These fi ndings refl ect that malignant nodules grow 
across the normal tissue plane in a centrifugal way, while 
benign nodules grow along the tissue plane in a parallel 
fashion (23-25). A nodule with an irregular shape is often 
seen in benign conditions such as focal thyroiditis as well 
as in malignant conditions (9). We suggest that the shape 
A B
C D
Fig. 1. Internal content of thyroid nodules.
A. Solid B. Predominantly solid C. Predominantly cystic D. Cystic
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of a nodule is categorized as follows: ovoid to round (when 
the anteroposterior diameter of a nodule is equal to or less 
than its transverse diameter on a transverse or longitudinal 
plane), taller-than-wide (when the anteroposterior diameter 
of a nodule is longer than its transverse diameter on a 
transverse or longitudinal plane) or irregular (when a 
nodule is neither ovoid to round nor taller-than-wide) (Fig. 
3). 
NODULE MARGIN
Earlier studies have reported that both a spiculated 
or microlobulated margin and an ill-defi ned margin are 
suggestive of malignancy (23, 26). With the development 
of high-frequency transducer US techniques, a previously 
described ill-defi ned margin could actually be a spiculated 
and jagged edge with sharp demarcation (a spiculated 
or microlobulated margin) or a poorly defi ned margin in 
which the tumor cannot be differentiated from the normal 
parenchyma (an ill-defi ned margin) (9). When the marginal 
tumor infi ltration is minimal, it can be seen as an ill-defi ned 
margin. In addition, benign thyroid nodules are known to 
be incompletely encapsulated and poorly marginated and 
they can merge with normal tissue (27). Therefore, an ill-
defi ned margin is a nonspecifi c fi nding that is seen for both 
benign and malignant nodules. In contrast, a spiculated 
margin is a highly suggestive fi nding of malignancy with a 
B CA
Fig. 3. Shape of thyroid nodules. Corresponding schematic drawings are shown in upper panel.
A. Ovoid-to-round shape B. Taller-than-wide shape C. Irregular shape
Fig. 2. US fi ndings of spongiform appearance are shown. 
Transverse US image of benign nodular hyperplasia shows well-
defi ned smooth isoechoic mass with a spongiform appearance 
(arrows).
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specifi city of 92% and a positive predictive value of 81% (9). 
Accordingly, we suggest that the margin of a nodule is 
categorized as follows: smooth, spiculated/microlobulated 
or ill-defi ned (Fig. 4).
ECHOGENICITY
In terms of echogenicity, a solid component must be 
considered. When a solid component is heterogeneous, the 
nodular echogenicity is defi ned by that of the majority of 
the nodule. Marked hypoechogenicity is highly specifi c for 
malignant nodule with a specifi city of 92-94% (9, 23). 
Although the parenchymal echogenicity of a thyroid gland 
can vary among individuals, it is used as a reference for 
nodule echogenicity. Another reference to defi ne nodule 
echogenicity is the strap muscles with low-echogenicity 
such as the sternothyroid muscle, the sternothyroid muscle 
and the sternocleidomastoid muscles (9, 23). 
We suggest that nodule echogenicity is categorized 
according to the relative echogenicity compared to that of 
a reference as follows. Nodule echogenicity includes marked 
hypoechoic (when a nodule is hypoechoic relative to the 
adjacent strap muscle), hypoechoic (when a nodule is 
hypoechoic relative to the thyroid parenchyma), isoechoic 
(when a nodule has the same echogenicity as that of the 
thyroid parenchyma) and hyperechoic (when a nodule is 
echogenic relative to the thyroid parenchyma) (Fig. 5). 
CALCIFICATION
Calcifi cations can be seen in both benign and malignant 
nodules. Calcifi cations may be microcalcifi cation, coarse 
or macrocalcifi cation or peripheral or rim calcifi cations 
in thyroid nodules. Pathologically, microcalcifi cation is a 
psammoma body that is comprised of 10-100 μm round, 
laminar, crystalline, calcifi c deposits, which is very specifi c 
for thyroid carcinoma, and especially for papillary thyroid 
carcinoma. 
Microcalcifi cations on US are fi ndings that are highly 
suggestive for malignancy with a specifi city of 86-95% 
A B
C
Fig. 4. Margin of thyroid nodules.
A. Smooth margin B. Spiculated or microlobulated margin (arrow) C. 
Ill-defi ned margin (arrows)
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and a positive predictive value of 42-94% (9, 23, 26, 28, 
29). Large and irregular shaped dystrophic calcifi cations 
may develop secondarily due to tissue necrosis and these 
calcifi cations can be seen in both benign and malignant 
nodules. A solid nodule with macrocalcifi cation larger than 
1 mm suggests the presence of a malignancy rather than 
a benign nodule (9). The meaning of peripheral, eggshell 
or rim calcifi cation is still being debated for making the 
differentiation between benign and malignant nodules. 
Recent reports have found that when a nodule has eggshell 
or rim calcifi cations, a hypoechoic halo and/or disruption 
of eggshell calcifi cations, these are fi ndings that suggest 
malignancy (9, 30-32). 
On US, a calcifi cation is defi ned as a prominent echogenic 
focus with or without posterior shadowing. The absence 
of posterior shadowing does not rule out the possibility 
of calcifi cation since some calcifi cations are too small to 
produce posterior shadowing. When punctuate echogenic 
foci are accompanied by reverberation artifacts, they 
should be due to colloid materials and they can be easily 
differentiated from calcifi cation on real-time US.  
We suggest that calcifi cation is categorized with respect to 
its size as follows. Calcifi cations include microcalcifi cations 
(when there are tiny, punctuate echogenic foci of 1 mm 
or less either with or without posterior shadowing), 
macrocalcifi cations (when punctuate echogenic foci are 
larger than 1 mm in size) and rim calcifi cations (when a 
nodule has peripheral curvilinear or eggshell calcifi cation) 
(Fig. 6). 
EXTRACAPSULAR INVASION
Extracapsular extension is observed in 36% of all thyroid 
A B
C D
Fig. 5. Echogenicity of thyroid nodules.
A. Marked hypoechogenicity of nodule is shown. Note more hypoechoic nature of nodule (arrow) as compared to that of strap muscles (asterisk). B. 
Hypoechogenicity of nodule (arrows) C. Isoechogenicity of nodule (arrows) D. Hyperechogenicity of nodule (arrow)
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carcinomas at surgery (26). Aggressive local invasion is 
relatively common in anaplastic carcinoma, lymphoma and 
sarcoma. Radiologist should observe whether a nodule 
crosses the thyroid capsule and invades the adjacent 
structure such as the trachea, esophagus and thyroid 
cartilage.
OTHER CHRACTERISTICS
The echotexture of a nodule may be homogeneous or 
heterogeneous. Echotexture is not a helpful fi nding in 
distinguishing malignant nodules from benign nodules (9). 
Sometimes a nodule show an accompanying hypoechoic 
thin or thick halo. A halo or hypoechoic rim surrounding a 
nodule is comprised of a pseudocapsule that is caused by 
fi brous connective tissue, compressed thyroid tissue and 
chronic infl ammatory change (33). Although a completely 
even halo is a fi nding suggestive of benign nodule with a 
specifi city of 95% in one study (34), more than a half of 
benign nodules lack a halo (18, 33). On the other hand, 
10-24% of all papillary carcinomas have a complete or 
incomplete halo (14, 17, 18, 34). 
TUMOR VASCULARITY
Color Doppler US or power Doppler US can be used for 
the evaluation of the intratumoral vascularity of thyroid 
nodules. Although intratumoral hypervascularity is observed 
in 69-74% of thyroid carcinomas, it is a nonspecifi c fi nding 
(17). Though perinodular fl ow is mainly a characteristic 
fi nding for benign nodules, it is observed in 22% of 
malignant nodules (17). According to several recent 
studies, the resistive index, the maximal systolic velocity 
and the vascularity pattern on Doppler US did not help 
to differentiate benign and malignant nodules (35, 36). 
Therefore, we do not recommend the routine use of color 
Doppler and power Doppler US for thyroid nodules. 
A B
C 
Fig. 6. Calcifi cations of thyroid nodules.
A. Microcalcifi cation within nodule as echogenic focus B. 
Macrocalcifi cation (arrow) in center of nodule (white triangles) C. Rim 
calcifi cation in small nodule (calipers).
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US ELASTOGRAPHY
US elastography is a new technique to measure the 
elasticity of tissue. The tissue of carcinoma is harder and 
fi rmer than that of the normal thyroid parenchyma or a 
benign nodule. Elastography quantifi es the fi rmness of the 
tissue and this is visualized as an elastography map. The 
strain index on elastography has been suggested as a good 
predictive factor for malignant thyroid nodules (37) (Fig. 7). 
US FINDINGS FOR BENIGN AND MALIGNANT 
NODULES
The known US fi ndings for malignant nodules are 
microcalcifi cations, the presence of hypoechoic nodule, an 
irregular margin, loss of the halo and the presence of a 
solid nodule as well as intratumoral vascularity (5, 24, 26, 
28, 29, 38-40). However, the different use of terminology, 
the variable sample size of the previously published data, 
the use of US instruments with different qualities and 
the different range of experience of radiologists and even 
diagnostic overlap of these fi ndings cause variable results 
of the diagnostic accuracy (4, 23, 26, 28, 29, 41). 
In the multicenter retrospective study that applied 
standardized terminology for US fi ndings as proposed earlier 
in this report (9), the signifi cant fi ndings for malignant 
nodules were a taller than wide shape (sensitivity, 40%; 
specifi city, 91%), a spiculated margin (sensitivity, 48%; 
specifi city, 92%), marked hypoechogenicity (sensitivity, 
41%; specifi city, 92%), microcalcifi cation (sensitivity, 
44%; specifi city, 91%), and macrocalcifi cation (sensitivity, 
10%; specifi city, 96%). The US fi ndings for benign nodules 
were isoechogenicity (sensitivity, 57%; specifi city, 88%) 
and a spongiform appearance (sensitivity, 10%; specifi city, 
100%). Although hypoechogenicity is a suggestive fi nding 
for being malignancy in many reports (4, 23, 26, 39), 
marked hypoechogenicity is a more specifi c and more 
reliable criterion for a malignant nodule (9, 23). In terms 
of the nodule size, a lower frequency of microcalcifi cation 
in microcarcinomas causes a lower sensitivity and this 
suggests that microcalcifi cation is not a major predictor 
of malignancy in nodules 1 cm or smaller. Although other 
fi ndings such as marked hypoechogenicity, a taller-than-
wide shape and a spiculated margin are slightly more 
frequent in subcentimeter malignant nodules, and they are 
also more frequent in subcentimeter benign nodules than in 
the larger counterparts. Accordingly, the false positive rate 
of depiction of a malignant nodule could be increased in 
smaller nodules (9, 42).
Although rim calcifi cation itself was not helpful for 
making a US diagnosis in a multicenter study, recent 
studies suggest that the presence of a hypoechoic halo and 
disruption of rim calcifi cation may be useful sonographic 
predictors of malignancy (32). In addition, according to 
previous studies, the fi ndings of a complete cystic lesion 
and a cystic lesion containing comet tail artifacts are 
very specifi c for benignancy (43). Therefore, we suggest 
the US criteria for benign and malignant thyroid nodules 
as is shown in Figure 8. We divided thyroid nodules into 
A B
Fig. 7. US elastography of thyroid nodules.
A. Elastography shows nodule with hard consistency as blue relative to green background. B. Longitudinal US image shows same nodule with 
suspicious malignant US features. Nodule was proven to be papillary carcinoma.
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three categories: suspicious malignant nodules, probably 
benign nodules and indeterminate nodules. A taller-than-
wide shape, a spiculated margin, marked hypoechogenicity, 
microcalcifi cations and macrocalcifi cations are suggestive 
fi ndings for malignancy. The presence of at least one 
of the fi ndings for malignancy defi nes a nodule as a 
suspicious malignant nodule. In contrast, a simple cyst, a 
predominantly cystic or cystic nodule with reverberating 
artifacts and a nodule with a spongiform appearance 
(especially with intervening isoechoic parenchyma) are 
defi ned as probably benign nodules. Although a cystic 
nodule with more than a 90% cystic component is very rare 
for a thyroid malignancy, a mural solid component within 
the cystic nodule may be papillary thyroid carcinoma (43). 
Therefore, a small solid component in a predominantly 
cystic or cystic nodule should be carefully examined and 
it should be aspirated in the case with the presence of a 
suspicious malignant feature. 
Indeterminate nodules include nodules having US fi ndings 
with neither malignant nor benign features. The US fi ndings 
for an indeterminate nodule include isoechogenicity, 
hypoechogenicity, and hyperechogenicity, an ovoid-to-round 
or irregular shape, a smooth or ill-defi ned margin and a rim 
calcifi cation. Although, isoechogenicity is more suggestive 
of benignancy, 14% of the isoechoic nodules were malignant 
in one study (9). Although rim calcifi cation is classifi ed as 
an indeterminate factor for malignancy,  the presence of a 
hypoechoic halo and rim disruption is more suggestive of 
malignancy (32). The indeterminate category is currently a 
term for all nodules that are without clear evidence of being 
benign and malignant. The criteria for suspicious malignant 
nodules are identical to the US fi ndings for papillary 
carcinoma, which comprises most thyroid carcinomas. The 
US fi ndings for medullary carcinoma are almost the same as 
those for papillary carcinoma (44). Yet these criteria have 
limited value in diagnosing thyroid carcinomas other than 
a subtype of papillary carcinoma. Relatively uncommon 
FTC and other histologic types of thyroid carcinoma can be 
eliminated by the use of these criteria (45, 46). Along with 
an accumulation of evidence from further studies on thyroid 
US, the indeterminate category can be subclassifi ed into 
truly benign nodule or adenoma or malignant nodule. 
INDICATIONS FOR US-GUIDED FINE-NEEDLE 
ASPIRATION BIOPSY ACCORDING TO THE US 
CRITERIA 
Our task force members established recommendations on 
the indications for US-guided fi ne-needle aspiration (USFNA) 
biopsy and follow-up for thyroid nodules fi rst in 2006 (10) 
and these were revised in 2009. In our recommendations, 
whether or not to perform a USFNA biopsy depends on the 
US fi ndings of a nodule (Fig. 8). 
When a single nodule is found on thyroid US, the 
presence of at least one malignant US fi ndings necessitates 
USFNA regardless of the size of the nodule. Evidence has 
shown that the mortality and rate of recurrence is directly 
proportional to the size of a thyroid tumor (47, 48). 
However, even a micropapillary thyroid carcinoma has a 
substantial number of lymph node metastases (8-50%) and 
a recurrence rate from 1% up to approximately 7% (49-53). 
The ATA guideline recommends that a subcentimeter nodule 
should be subjected to a biopsy only if the nodule has a 
suspicious fi nding or the patient has a personal history of 
radiation exposure or familial thyroid cancer (8). Among 
the subcentimeter cancers, a carcinoma smaller than 5 mm 
has a better survival rate and a better recurrence rate at 5 
year (less than 3% versus 14% for carcinoma that is 6-10 
mm in diameter) (54). Regarding the size issue, recent 
studies have recommended not to biopsy nodules smaller 
than 5 mm in size because of a high rate of false positive 
US fi ndings as well as a high rate of inadequate cytology 
(55, 56). We recommend performing FNA for a nodule of 
any size that has suspicious malignant fi ndings if FNA 
Fig. 8. Flowchart for strategy for follow-up US and US-guided 
fi ne needle aspiration (USFNA) biopsy according to US fi ndings 
and cytology results of thyroid nodules. 
Dotted arrow means that surgery is not strongly recommended, but it 
can be considered according to individual situations. AUS = atypia of 
undetermined signifi cance, FLUS = follicular lesion of undetermined 
signifi cance. 
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is feasible and a nodule is larger than 5 mm in size. For 
a nodule smaller than 5 mm, selective FNA can be done 
according to patient’s risk factors and the experience of the 
radiologists. This recommendation relies on the fact that 
there is still debate concerning the fate and prognosis of 
microcarcinomas, as was described above.
If a nodule has indeterminate fi ndings on US and it 
is larger than 1 cm in diameter, then performing FNA 
is recommended due to the fact that the possibility 
of malignancy cannot be excluded. If a nodule has 
indeterminate fi ndings and it is 1 cm or less in size, then 
an FNA biopsy is not necessary and follow-up US would 
suffi ce. If a benign appearing nodule is larger than 1 cm, 
then we recommend performing follow-up US in two years 
and thereafter at 3-5 year intervals. If a benign appearing 
nodule (i.e., a spongiform nodule) is larger than 2 cm, then 
selective FNA biopsy can be done. Neither FNA nor follow 
up US is necessary for a spongiform nodule and a benign 
appearing nodule 1 cm or less in diameter. 
When multiple nodules are found on US, not all of the 
nodules have to be biopsied. The risk of malignancy for 
patients with multiple thyroid nodules is not greatly 
different from that for patients with a single thyroid nodule 
(8, 26). According to the ATA guideline (8), in the presence 
of two or more nodules 1-1.5 cm or more in size, a FNA 
biopsy is recommended for nodules with suspicious US 
fi ndings. If none of the nodules has suspicious US fi ndings, 
then FNA should be done for the largest one. Multifocality 
and bilaterality is not uncommon and even in thyroid 
microcarcinomas (49). Furthermore, some investigators 
believe multifocality and bilaterality are linked to higher 
recurrence and higher mortality (48, 50). Therefore, 
multiple and bilateral nodules should not be regarded as a 
multinodular goiter consisting of benign nodules.  
In the case of multiple nodules of the thyroid, we choose 
the nodules to be biopsied according to the US fi ndings. 
We recommend aspirating one or more nodules that meet 
the US criteria of a nodule, but not to depend on the size 
criteria. We recommend aspirating at least one nodule for 
each lobe and at least one nodule (the largest) among 
multiple nodules that have similar US fi ndings. A nodule 
should not be chosen for a biopsy only on the size criteria 
alone. 
Some thyroid nodules may grow steadily as seen on 
follow-up US, even though they were diagnosed as being 
benign on the previous cytology. In these cases, a decision 
should be made on whether or not to perform a biopsy. 
The rate of nodule growth on US cannot distinguish benign 
from malignant nodules (57). In one study of 420 benign 
nodules, one-third of benign nodules showed growth of 
a 15-30% increase in volume, one-third of the benign 
nodules showed no change in growth and one-third showed 
a decrease in size (58). The measurement of small nodule 
reportedly is not reliable as substantial interobserver bias 
has been observed in the measurement of small nodules, 
and especially for less than a 50% volume increase (16). 
Despite the debate concerning signifi cant size change, we 
advise to selectively biopsy a growing nodule according 
to the size change criteria adopted from the ATA guideline 
(8). We do recommend an FNA biopsy be performed if 
an indeterminate nodule is growing. If a benign nodule 
is growing, then we do not recommend performing an 
immediate FNA biopsy in every incidence. At least one more 
follow-up US exams can be selectively advised. 
When a malignant lymph node is suspected, it is necessary 
to biopsy any suspicious lymph node in the lateral neck area 
as well as a thyroid nodule regardless of the nodule’s size 
and features. While central neck dissection is performed in 
almost all the patients with thyroid papillary carcinoma, 
lateral neck dissection (levels II-V) is selectively done for 
patients who have a preoperative diagnosis of lymphatic 
metastasis. Therefore, USFNA for suspicious lymph nodes in 
the lateral neck area (levels II-V) is important for making 
decisions about surgical management (8). 
FOLLOW-UP US AND US FINE-NEEDLE 
ASPIRATION BIOPSY ACCORDING TO THE US 
FINDINGS AND CYTOLOGY RESULTS
When the initial US fi ndings are probably benign, a US-
FNA biopsy is not necessary and follow-up US or clinical 
observation is advisory for a nodule’s change. Among the 
probably benign nodules on US, a complete cystic or cystic 
nodule with reverberating artifacts and spongiform nodules 
can be placed under clinical observation alone. In contrast, 
the patients with a probably benign nodule larger than 1 
cm are recommended to undergo follow-up by US in two 
years and thereafter at a 3-5 year interval. 
When the initial US fi ndings are suspicious for malignant 
or they are indeterminate, the fate of thyroid nodules is 
dependent on the adequately classifi ed cytology results 
(59). If the cytology of the nodule results in nondiagnostic 
aspirates, then the presence of malignant US fi ndings 
determines the next step for the management of the 
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nodule. Non-diagnostic cytology results occur in 5-10% of 
cases under US guidance and these non-diagnostic cases 
are due to the operator’s inexperience, aspiration of cystic 
fl uid and the presence of a bloody aspirate (38). Five 
percent of nodules with nondiagnostic cytology after an 
initial biopsy are eventually diagnosed as malignant and 
approximately 18% of malignant nodules are diagnosed 
by at least two aspiration cytology examinations (60, 61). 
Therefore, thyroid nodules with non-diagnostic cytology and 
malignant US fi ndings should be followed by US-FNA biopsy 
at a 3-6 month interval. When a nodule does not have any 
malignant US fi ndings, but it has non-diagnostic cytology, 
it is recommended that the nodule should be followed up 
by US-FNA biopsy in 6-12 months.
When the cytology result for a nodule is malignant, 
the patient should undergo surgery and follow-up by 
US (7, 8). When the cytology results of thyroid nodules 
are indeterminate (suspicious for a papillary carcinoma, 
atypical cells, follicular lesion or follicular neoplasm), the 
subtype of the indeterminate cytology and the presence 
of malignant US fi ndings determines the next step for the 
nodules’ management. An indeterminate cytology fi nding, 
although the cytology results can vary as determined at 
different institutions, is responsible for approximately 
15-30% of all the fi ne needle aspiration cytologies. The 
cytology results of a suspicious for papillary carcinoma or 
Hurthle cell neoplasm necessitates surgery (lobectomy or 
total thyroidectomy) followed by US. When the cytology 
of a nodule is indicative of a follicular neoplasm, it is 
recommended to consider surgery fi rst although repeated 
US-FNA biopsies are preferable in certain situations. When 
the cytology of a nodule is a follicular lesion of undetermined 
signifi cance or atypia of undetermined signifi cance (59), a 
nodule 1 cm or more is recommended to undergo a repeated 
US-FNA biopsy in 6-12 months in the case of malignant US 
fi ndings, while a nodule without malignant US fi ndings can 
be subjected to a repeated US-FNA in 1-1.5 years. 
When the cytology of a nodule is indicative of being 
benign, the follow-up strategy is as follows and according 
to the US fi ndings. A nodule with malignant US fi ndings is 
recommended to undergo repeat US-FNA in 6-12 months, 
while a nodule without malignant fi ndings is recommended 
to undergo repeat US in one year or to repeat US-FNA 
selectively. Since the false-negative rate of USFNA is low 
but not negligible, it is reasonable to repeat US-FNA in 
certain conditions, and especially for thyroid nodules 
with malignant US fi ndings (62). A nodule with a benign 
cytology and that has been subjected to at least two US-
FNA biopsies is regarded as a benign nodule and it can be 
followed up in 3-5 years. 
ROLE OF THYROID US AS A SCREENING TEST
The role of a screening test for thyroid nodules is limited. 
Because of the very high prevalence of thyroid nodules 
and the very good prognosis and survival rate, the current 
consensus is that a screening test for thyroid malignancy 
cannot be justifi ed (7). As smaller malignant nodules can be 
detected on thyroid US, the survival rate and prognosis may 
improve regardless of the actual effect of the treatments, 
and even with an increasing prevalence of disease (54, 63). 
Thyroid cancer detected by the use of an early screening 
test may tend to progress less rapidly than clinically 
detected disease. There may be cases that would regress, 
remain stable or progress too slowly to become clinically 
apparent during the lifetime of the patient (63).
However, a screening test can be justifi ed in high-risk 
groups such as patients with a history of familial thyroid 
carcinoma, a history of MEN or a history of childhood 
irradiation of the head and neck area. 
CONCLUSION
US for thyroid nodules is the most sensitive diagnostic 
modality for making the diagnosis of thyroid carcinoma 
and this modality provides valuable guidance to 
perform an aspiration biopsy and follow-up. On the US 
of thyroid nodule, the size of the nodule, the internal 
texture, the shape, the echogenicity, the margin, the 
presence of calcifi cation and the presence of adjacent 
structures should be carefully scrutinized. The fi ndings 
for a suspicious malignant nodule include a taller-
than-wide shape, a spiculated or microlobulated 
margin, marked hypoechogenicity, microcalcifi cations 
and macrocalcifi cations. Presence of at least one of 
the malignant US fi ndings suggests the presence of a 
malignancy. According to these fi ndings and the resultant 
category of a nodule, the nodule should be aspirated or 
followed-up with US, or it should remain under clinical 
observation. 
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